In vitro studies on the mechanism of action of VEGF and its inhibitors;In-vitro-untersuchungen zum wirkungsmechanismus von VEGF und seinen inhibitoren

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 7, 2008, Pages 623-628

  Deissler, Heidrun L ^a   Lang, G E ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Diabetic retinopathy; Retinal microvascular endothelial cells; VEGF; VEGF inhibitors

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CYTOPLASM; DIABETIC RETINOPATHY; DRUG MECHANISM; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; PROTEIN BINDING; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TIGHT JUNCTION;

ANIMALS; DIABETIC RETINOPATHY; EPITHELIAL CELLS; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 50149105887     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027513     Document Type: Review

References (34)

1. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. NEJM 1994; 331: 1480-1487
2. Antonetti DA, Barber AJ, Hollinger LA et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens 1. J Biol Chem 1999; 274: 23463-23467
3. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost 2006; 95: 36-42
4. Behzadian MA, Windsor LJ, Ghaly N et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003; 17: 752-754
5. Boulton M, Foreman D, Williams G et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561-568
6. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-455
7. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005; 6: 511-524
8. Deissler H, Deissler H, Lang GK et al. Generation and characterization of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. Int J Mol Med 2005; 16: 65-70
9. Deissler H, Deissler H, Lang GK et al. TGFβ induces transdifferentiation of iBREC to &alphaSMA-expressing cells. Int J Mol Med 2006; 18: 577-582
10. Deissler H, Deissler H, Lang S et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis®) in microvascular retinal endothelial cells. Br J Ophthalmol 2008; im Druck
11. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611
12. Ferrara N, Damico L, Shams N et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870
13. Hammes H-P, Lin J, Renner O et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002; 51: 3107-3112
14. Harhaj NS, Felinski EA, Wolpert EB et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47: 5106-5115
15. Hughes JM, Brink A, Witmer AM et al. Vascular leucocyte adhesion molecules unaltered in the human retina in diabetes. Br J Ophthalmol 2004; 88: 566-572
16. Joussen AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450-1452
17. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12: 5018-5022
18. Lowe J, Araujo J, Yang J et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007; 85: 425-430
19. Lutty GA, Mathews MK, Merges C et al. Adenosine stimulates canine retinal microvascular endothelial cell migration and tube formation. Curr Eye Res 1998; 17: 594-607
20. Malik RA, Li C, Aziz W et al. Elevated plasma CD 105 and vitreous VEGF levels in diabetic retinopathy. J Cell Mol Med 2005; 9: 692-697
21. McLeod DS, Lefer DJ, Merges C et al. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995; 147: 642-653
22. Pan Q, Chathery Y, Wu Y et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007; 282: 24049-24056
23. Peters S, Julien S, Heiduschka P et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91: 827-831
24. Qaum T, Xu Q, Joussen AM et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42: 2408-2413
25. Raja TT, Grammas P. VEGF and VEGF receptor levels in retinal and brain-derived endlthelial cells. Bioch Biophys Res Commun 2002; 293: 710-713
26. Sakakibara A, Furuse M, Saitou M et al. Possible involvement of phosphorylation of occludin in tight junction formation. J Cell Biol 1997; 137: 1393-1401
27. Spitzer MS, Wallenfels-Thilo B, Sierra A et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006; 90: 1316-1321
28. Spitzer MS, Yoeruek E, Sierra A et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1837-1842
29. Suzuma K, Takagi H, Otani A et al. Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 1998; 39: 1028-1035
30. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001; 2: 285-293
31. Vinores SA. Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther 2003; 5: 673-679
32. Watanabe D, Suzuma K, Suzuma I et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139: 476-481
33. Witmer AN, Blaauwgeers HG, Weich HA et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 43: 849-857
34. Wong V. Phosphorylation of occludin correlates with occludin localization and funciton at the tight junction. Am J Physiol 1997; 273: C1859-1867